In a recent glioblastoma study, researchers modified the surface of IFN-γ mRNA loaded EVs with anti-CD71 and anti-programmed cell death-ligand 1 (PD-L1) antibodies and demonstrated an increase in uptake and antitumor activity as compared to unmodified EVs 148. This evidence concerns the gene CD274 and glioblastoma.